navelbine 10 mg/ml infuusiokonsentraatti, liuosta varten
pierre fabre pharma norden ab - vinorelbine ditartrate - infuusiokonsentraatti, liuosta varten - 10 mg/ml - vinorelbiini
navelbine 20 mg kapseli, pehmeä
pierre fabre pharma norden ab - vinorelbine tartrate - kapseli, pehmeä - 20 mg - vinorelbiini
navelbine 30 mg kapseli, pehmeä
pierre fabre pharma norden ab - vinorelbine tartrate - kapseli, pehmeä - 30 mg - vinorelbiini
navelbine 80 mg kapseli, pehmeä
pierre fabre pharma norden ab - vinorelbine tartrate - kapseli, pehmeä - 80 mg - vinorelbiini
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
navelbine 40 mg kapseli, pehmeä
pierre fabre pharma norden ab - vinorelbini tartras - kapseli, pehmeä - 40 mg - vinorelbiini
navelbine 10 mg/ml infuusiokonsentraatti, liuosta varten
orifarm oy - vinorelbini tartras - infuusiokonsentraatti, liuosta varten - 10 mg/ml - vinorelbiini
navelbine 20 mg kapseli, pehmeä
paranova oy - vinorelbini tartras - kapseli, pehmeä - 20 mg - vinorelbiini
navelbine 30 mg kapseli, pehmeä
paranova oy - vinorelbini tartras - kapseli, pehmeä - 30 mg - vinorelbiini
fampyra
biogen netherlands b.v. - fampridine - multippeliskleroosi - muut hermoston huumeet - fampyra on tarkoitettu parantamaan kävelyä aikuispotilailla, joilla on multippeliskleroosi ja kävelysairaus (laajennettu vammaisuuden tilan asteikko 4-7).